drugset / Trial / NCT04914403
Mesenchymal Stem Cells for The Treatment of Frailty Syndrome
NaSequentialOpen-labelTreatment
Summary
The clinical study with UMC119-06-05 is designed to investigate the safety in patients with frailty syndrome. This will be a dose escalation, open label, single-center study in adult with frailty syndrome. UMC119-06-05 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of frailty syndrome.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2024-12
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | — | Intravenous |
Indications
No indication recorded.